Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 study.
Hum Vaccin ImmunotherJul 13, 2026 (epub)
Carlos Fierro, Miaoxin Lin, Bethany Girard et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 2 randomized controlled trial evaluated the safety and immunogenicity of three mRNA-1010 influenza vaccine compositions in 270 healthy adults aged 18-49 in the U.S. The study found that all compositions were well tolerated and induced higher immune responses against influenza B strains compared to the original mRNA-1010 composition.
Key findings
- All mRNA-1010 compositions were well tolerated with no safety concerns identified.
- All compositions induced HA-specific humoral and cellular immune responses against evaluated influenza strains.
- Optimized mRNA-1010 compositions showed enhanced immune responses against influenza B strains compared to the original composition.
Why it matters
The findings suggest that mRNA-based vaccines may provide improved protection against seasonal influenza, particularly against influenza B strains, which could enhance public health strategies for influenza prevention.